




PHARMACEUTICAL 2021

Sio Gene Therapies Inc.
Rank 248 of 402





RealRate

PHARMACEUTICAL 2021

Sio Gene Therapies Inc.
Rank 248 of 402



The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 4.7% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	85,430
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,043
Liabilities, Non-Current	79
Other Assets	7,449
Other Compr. Net Income	-966
Other Expenses	4,815
Other Liabilities	0
Other Net Income	1,358
Other Revenues	0
Property and Equipment	801
Research and Development	47,110
Selling, General and Administrative Expense	22,061

Output Variable	Value in 1000 USD
Assets	93,680
Liabilities	32,122
Expenses	73,986
Revenues	0
Stockholders Equity	61,558
Net Income	-72,628
Comprehensive Net Income	-73,111
Economic Capital Ratio	52%